Results 11,161-11,180 of 12,718 for speaker:Louise O'Reilly

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: I have some short questions for the witnesses. On the potential for developing our own drugs, we have a thriving third level sector and a huge amount of money is being invested into skilling-up our scientists and fitting out our universities. Is there a reason why we are not developing more of our own drugs, and with the involvement of the State in the provision of those services can we not...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: I am talking about development. Where they are physically made is not that important. Our universities are working in tandem and in partnership with these multinationals and yet we do not seem to get any benefit. We are still building the labs and staffing them, and yet we are not getting any benefit back. From the witness's reaction I can see that that is not happening, but it strikes me...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: I thank Mr. Hennessy, Mr. Flanagan, Mr. Mitchell, Professor Barry and Dr. Tilson for their time and their answers.

Joint Oireachtas Committee on Health: Funding of Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: We are joined for this session by representatives of the Alpha One Foundation, an advocacy group for Respreeza, and Muscular Dystrophy Ireland, an advocacy group for Translarna, to discuss the subject of funding for orphan drugs. On behalf of the committee, I welcome Ms Geraldine Kelly and Professor Gerry McElvaney of the Alpha One Foundation and Ms Clair Kelly and Mr. Richard Lodge of...

Joint Oireachtas Committee on Health: Funding of Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: I welcome the representative of Muscular Dystrophy Ireland, Mr. Lodge, and invite him to make his opening remarks.

Joint Oireachtas Committee on Health: Funding of Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: I thank Mr. Lodge. I call Deputy Durkan, followed by Deputy Brassil.

Joint Oireachtas Committee on Health: Funding of Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: I have some questions and then I will come to Deputy Murphy O'Mahony and Senator Colm Burke. Ms Kelly spoke about deadlines. Could she provide an insight on behalf of the people she is here to represent of the kind of impacts those deadlines have on families and the individuals themselves? It must be horrendous for them. I have met people in my constituency who were affected and the...

Joint Oireachtas Committee on Health: Funding of Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: I do not want to put words into anyone's mouth but it was less than an hour ago so I think I remember what was said. The HSE seemed to be indicating that it does listen to patients and that patients and advocacy groups have a mechanism for input.

Joint Oireachtas Committee on Health: Funding of Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: I was not trying to compare the two.

Joint Oireachtas Committee on Health: Funding of Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: We could round it up to two years.

Joint Oireachtas Committee on Health: Funding of Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: I would imagine it is the same for a range of conditions.

Joint Oireachtas Committee on Health: Funding of Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: Deputy Durkan and others indicated that it does seem we speak much about co-operation at a European level but on this issue there seems to be none. The witnesses were here when we questioned the HSE and I did so myself. We asked about European standards and they just do not seem to exist. It strikes me that it is an area on which we should put a heavy focus.

Joint Oireachtas Committee on Health: Funding of Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: It should be the first port of call.

Joint Oireachtas Committee on Health: Funding of Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: That issue is central to both cases. When we put a straight-up question to the HSE such as does it consider everything, it answers yes. I have met numerous advocacy groups, as we all have, and the point keeps being made that if it did actually look at the real savings involved, the conclusion could not be anything other than that the drug is cost effective. There is obviously some slippage...

Joint Oireachtas Committee on Health: Funding of Orphan Drugs: Discussion (12 Jul 2017)

Louise O'Reilly: On behalf of the committee, I thank Professor McElvaney, Mr. Lodge and Ms Kelly for coming before us and putting their case so eloquently. I am glad that they had the opportunity to listen to the HSE and the NCPE. It is helpful for those who are advocates who are welcome to attend public sessions of the committee at any time to see that when representatives of the HSE and NCPE come before...

Select Committee on Health: Health and Social Care Professionals (Amendment) Bill 2017: Committee Stage (11 Jul 2017)

Louise O'Reilly: I move amendment No. 1:In page 3, between lines 14 and 15, to insert the following:“Amendment of section 4 of Principal Act 2. Section 4(1) of Principal Act is amended by the insertion of the following after paragraph (l):“(m) counsellors, that is to say, a person or organisation who engages in, and holds himself, herself or itself out as having experience or expertise to...

Select Committee on Health: Health and Social Care Professionals (Amendment) Bill 2017: Committee Stage (11 Jul 2017)

Louise O'Reilly: As we sit here today women with crisis pregnancies are faced with these individuals who do not seek to give them information but only to traumatise them. It is absolutely necessary that these individuals are regulated. I accept the Minister's assurances that we will see substantial progress when we resume in the autumn. It is on that basis that I shall not press the amendment. I reserve...

Select Committee on Health: Health and Social Care Professionals (Amendment) Bill 2017: Committee Stage (11 Jul 2017)

Louise O'Reilly: I move amendment No. 4:In page 5, to delete lines 17 to 20 and substitute the following:“(a) applies on or after the date on which section 6(b) of the Health and Social Care Professionals (Amendment) Act 2017 comes into operation and not later than 30 September 2018, to the Physiotherapists Registration Board for registration, provided however that a person who is due to complete the...

Select Committee on Health: Health and Social Care Professionals (Amendment) Bill 2017: Committee Stage (11 Jul 2017)

Louise O'Reilly: The amendment proposes to bring forward the date from 2019 to 2018 and also to ensure the assessment of competence for applicants will be at the level of the physiotherapist qualification. It is important that all registrants have the same level of professional competence to ensure there is understanding of their role and function, not by them as professionals but by members of the general...

Select Committee on Health: Health and Social Care Professionals (Amendment) Bill 2017: Committee Stage (11 Jul 2017)

Louise O'Reilly: Yes, on the basis of the discussion we just had while reserving the right to table it again on Report Stage.